RVL Pharmaceuticals plc

OTCPK:RVLP.Q Voorraadrapport

Marktkapitalisatie: US$111.0

RVL Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for RVL Pharmaceuticals.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.7%
Inkomstengroein/a
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

None

Laatst bijgewerktn/a

Recente toekomstige groei-updates

Recent updates

RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 16
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

May 13
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

May 12
RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Apr 20
RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

Jan 05
Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M

Oct 18

RVL Pharmaceuticals: Chapter 2 - A Developing Quandary

Sep 22

RVL Pharma in pact with Revision Skincare to broaden access to products

Aug 30

GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M

Aug 11

RVL Pharma posts preliminary 42% sales growth for eye treatment

Jul 07

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Jul 04
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture

Jun 15

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Apr 01
New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Mar 30

Osmotica: A Different Breed Of Cat

Dec 14

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Aug 20
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Osmotica: Paring Down, Focusing On UPNEEQ

Jul 16

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat RVL Pharmaceuticals onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:RVLP.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
6/30/202337-68-47-44N/A
3/31/202337-56-32-30N/A
12/31/202250-52-39-38N/A
9/30/202243-53-46-46N/A
6/30/202235-66-52-52N/A
3/31/202238-76-58-57N/A
12/31/202118-83-49-55N/A
9/30/202116-115-34-39N/A
6/30/202140-86-9-13N/A
3/31/202128-82116N/A
12/31/202028-891518N/A
9/30/202087-642327N/A
6/30/2020126-1785154N/A
3/31/2020183-2853540N/A
12/31/2019240-2713034N/A
9/30/2019246-3515963N/A
6/30/2019247-2432933N/A
3/31/2019261-1122124N/A
12/31/2018264-1103338N/A
9/30/2018274-11429N/A
6/30/2018262-10319N/A
3/31/2018248-312745N/A
12/31/2017246-413858N/A
12/31/2016218-42N/A-45N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if RVLP.Q's forecast earnings growth is above the savings rate (2.5%).

Winst versus markt: Insufficient data to determine if RVLP.Q's earnings are forecast to grow faster than the US market

Hoge groeiwinsten: Insufficient data to determine if RVLP.Q's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if RVLP.Q's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: Insufficient data to determine if RVLP.Q's revenue is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if RVLP.Q's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven